Why the study?
In patients with congenital heart disease causing significant left-to-right shunting who are at risk for PAH, the mechanism by which pulmonary overcirculation and shear stress drive vascular remodeling remains poorly understood.
Smooth muscle cell-derived CXCL12 plays a key role in flow-induced vascular remodeling in pulmonary hypertension, offering a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for targeting SMC CXCL12 in PAH-CHD; leaves open efficacy in this new flow-hypoxia model.
Patients with congenital heart disease causing significant left-to-right shunting of blood are at risk of developing pulmonary arterial hypertension (PAH). However, the underlying mechanism by which pulmonary overcirculation and shear stress drive vascular remodeling remains poorly understood. Our study established a "two-hit" murine model of severe pulmonary hypertension by combining left pneumonectomy (LP) and chronic hypoxia (LP/Hx). Using transgenic reporter lines, immunofluorescence staining, and advanced microscopy, we conducted cell-lineage tracing for vascular cells, including smooth muscle cells (SMCs), endothelial cells, and pericytes. Our findings reveal that SMCs are key contributors to the distal arteriolar remodeling following LP and LP/Hx. PCR analysis of SMCs isolated from LP/Hx animals demonstrated upregulation of markers associated with contractility, proliferation, and Cxcl12 expression. Consistently, CXCL12 was found to be overexpressed in the SMC layer of pulmonary vessels from patients with PAH-congenital heart disease. Lastly, in vitro experiments with healthy human pulmonary artery SMCs showed that laminar shear stress induces CXCL12 upregulation. These findings provide novel insights into the role of SMCs in flow-induced vascular remodeling and their mechanosensitive response to shear stress. This murine model of severe pulmonary hypertension is a valuable tool for future research and developing targeted therapeutics for patients with PAH.
No takes yet. Share an insight, caveat, or question.
Klouda et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: